Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of PD-1/PD-L1 immunotherapy. Moreover, studies on transarterial chemoembolization (TACE) and programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy have demonstrated some interesting outcomes. This article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 immunotherapy. Overall, our review summarized that a favorable survival time could be achieved using this combination in most patients. However, complications such as hyperprogression should be taken seriously, and the underlying mechanisms need to be explored.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
